Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

James, Dan's strategy would have never created homerun "to shareholders" because of his reckless cash burn rate, lack of focused strategy and ongoing required dilution to kick the can down the road. The Board recognized as much, which is why Dan is no longer with us and there is a renewed "alignment" and "focus" and "fiscal restraint" at the company as emphasized in the press release. I for one feel much better now about the company's future and prospects for a return on investment to finally be realized under Lombardo. I hope he is made permanent CEO. I suspect he will if he lands a material deals that minimizes the need for more dilution.